TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) — Market Cap & Net Worth
Market Cap & Net Worth: TNF Pharmaceuticals, Inc. (TNFA)
TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) has a market capitalization of $6.80 Million ($6.80 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27752 globally and #5484 in its home market, demonstrating a -12.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TNF Pharmaceuticals, Inc.'s stock price $3.68 by its total outstanding shares 1846930 (1.85 Million). Analyse TNFA cash flow metrics to see how efficiently the company converts income to cash.
TNF Pharmaceuticals, Inc. Market Cap History: 2015 to 2025
TNF Pharmaceuticals, Inc.'s market capitalization history from 2015 to 2025. Data shows change from $25.74 Billion to $6.80 Million (-60.38% CAGR).
Index Memberships
TNF Pharmaceuticals, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #812 of 976 |
Weight: TNF Pharmaceuticals, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
TNF Pharmaceuticals, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TNF Pharmaceuticals, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1804.38x
TNF Pharmaceuticals, Inc.'s market cap is 1804.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $25.74 Billion | $2.12 Million | -$9.31 Million | 12172.16x | N/A |
| 2016 | $40.43 Billion | $2.96 Million | -$3.30 Million | 13653.09x | N/A |
| 2017 | $2.85 Billion | $3.35 Million | -$7.37 Million | 849.87x | N/A |
| 2018 | $3.01 Billion | $1.67 Million | -$10.85 Million | 1804.38x | N/A |
Competitor Companies of TNFA by Market Capitalization
Companies near TNF Pharmaceuticals, Inc. in the global market cap rankings as of May 4, 2026.
Key companies related to TNF Pharmaceuticals, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
TNF Pharmaceuticals, Inc. Historical Marketcap From 2015 to 2025
Between 2015 and today, TNF Pharmaceuticals, Inc.'s market cap moved from $25.74 Billion to $ 6.80 Million, with a yearly change of -60.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $6.80 Million | +219.99% |
| 2024 | $2.12 Million | -85.20% |
| 2023 | $14.35 Million | -77.48% |
| 2022 | $63.72 Million | -81.02% |
| 2021 | $335.77 Million | +52.26% |
| 2020 | $220.52 Million | -37.81% |
| 2019 | $354.61 Million | -88.20% |
| 2018 | $3.01 Billion | +5.41% |
| 2017 | $2.85 Billion | -92.95% |
| 2016 | $40.43 Billion | +57.02% |
| 2015 | $25.74 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of TNF Pharmaceuticals, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.80 Million USD |
| MoneyControl | $6.80 Million USD |
| MarketWatch | $6.80 Million USD |
| marketcap.company | $6.80 Million USD |
| Reuters | $6.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TNF Pharmaceuticals, Inc.
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rh… Read more